Home / Business and Economy / Natco Pharma's Credit Rating Affirmed by ICRA
Natco Pharma's Credit Rating Affirmed by ICRA
2 Dec, 2025
Summary
- Natco Pharma's debt instruments received reaffirmed credit ratings from ICRA.
- The company's stock price saw a 5% surge following the rating announcement.
- Natco Pharma's market capitalization reached ₹16,378.70 crore on BSE.
ICRA Limited has reaffirmed and assigned credit ratings to Natco Pharma's diverse debt instruments, according to a recent regulatory filing. The ratings agency has confirmed the long-term and short-term fund-based working capital limits at [ICRA]AA (Stable)/[ICRA]A1+, alongside similar affirmations for non-fund based working capital limits. This assessment reflects confidence in the company's financial stability and operational capabilities.
Following this news, Natco Pharma's shares experienced a notable uptick, rising 5% to ₹922.15 on the BSE on December 1, 2025. The pharmaceutical counter attracted considerable buying interest, with nearly 3 million equity shares trading hands by midday, indicating positive investor sentiment. The company's market capitalization was reported at ₹16,378.70 crore.
Further financial indicators presented by Natco Pharma include a trailing twelve-month EPS of 85.79 and a return on equity of 22.18%. The reaffirmation of ratings for various debt facilities, including term loans and commercial paper programs, highlights the sustained creditworthiness of the company in the market.
